KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Other Non-Current Liabilities (2016 - 2026)

Gsk has reported Other Non-Current Liabilities over the past 18 years, most recently at -$1.4 billion for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities fell 8.08% year-over-year to -$1.4 billion; the TTM value through Mar 2026 reached -$1.4 billion, down 8.08%, while the annual FY2025 figure was -$1.4 billion, 196.38% down from the prior year.
  • Other Non-Current Liabilities for Q1 2026 was -$1.4 billion at Gsk, down from -$1.4 billion in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $1.4 billion in Q4 2024 and troughed at -$1.4 billion in Q2 2024.
  • A 5-year average of -$756.1 million and a median of -$1.3 billion in 2025 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 99.26% in 2022 and later crashed 13367.05% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $1.1 billion in 2022, then soared by 30.3% to $1.4 billion in 2023, then grew by 2.76% to $1.4 billion in 2024, then tumbled by 196.38% to -$1.4 billion in 2025, then dropped by 3.04% to -$1.4 billion in 2026.
  • Business Quant data shows Other Non-Current Liabilities for GSK at -$1.4 billion in Q1 2026, -$1.4 billion in Q4 2025, and -$1.4 billion in Q3 2025.